These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 26746341)

  • 1. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
    Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
    Shu X; Zhang Y; Li M; Huang X; Yang Y; Zeng J; Zhao Y; Wang X; Zhang W; Ying Y
    Neuropharmacology; 2019 Jul; 153():1-12. PubMed ID: 31015047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.
    Qi L; Ke L; Liu X; Liao L; Ke S; Liu X; Wang Y; Lin X; Zhou Y; Wu L; Chen Z; Liu L
    Eur J Pharmacol; 2016 Jul; 783():23-32. PubMed ID: 27131827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
    Köhler C; Fuhr V; Dinekov M
    Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.
    Popelová A; Pražienková V; Neprašová B; Kasperová BJ; Hrubá L; Holubová M; Zemenová J; Blum D; Železná B; Galas MC; Kuneš J; Maletínská L
    J Alzheimers Dis; 2018; 62(4):1725-1736. PubMed ID: 29614684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
    Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
    Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
    Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
    PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice.
    Frederick C; Ando K; Leroy K; Héraud C; Suain V; Buée L; Brion JP
    J Alzheimers Dis; 2015; 44(4):1145-56. PubMed ID: 25408212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
    Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
    Rodríguez-Navarro JA; Rodríguez L; Casarejos MJ; Solano RM; Gómez A; Perucho J; Cuervo AM; García de Yébenes J; Mena MA
    Neurobiol Dis; 2010 Sep; 39(3):423-38. PubMed ID: 20546895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.